Lv5
1578 积分 2022-10-25 加入
Tumour necrosis factor and cancer
1天前
已完结
Combining TNF blockade with immune checkpoint inhibitors in patients with cancer
1天前
已完结
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary
1天前
已完结
Ozoralizumab: First Approval
1天前
已完结
Metabolic Messengers: tumour necrosis factor
1天前
已完结
Abatacept for the treatment of psoriatic arthritis
1天前
已完结
Iparomlimab and Tuvonralimab: First Approval
2天前
已完结
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis
2天前
已完结
A comprehensive review of immune checkpoint inhibitors for cancer treatment
4天前
已完结
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
4天前
已完结
皖公网安备34019202002308
